Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
FDA released final guidance on assessing adhesion for transdermal and topical delivery systems in ANDAs, providing standardized methods and criteria for evaluation.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic drug manufacturers developing abbreviated new drug applications (ANDAs) for transdermal and topical delivery systems. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline stated; guidance is effective immediately upon publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued final guidance outlining recommended approaches for assessing adhesion of transdermal and topical delivery systems in ANDA submissions.
Who it affects
Generic drug manufacturers developing abbreviated new drug applications (ANDAs) for transdermal and topical delivery systems.
What you must do
Review the final guidance and update ANDA development and testing protocols to align with the recommended adhesion assessment methods.
Deadline
No specific deadline stated; guidance is effective immediately upon publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - vitallaw.com
- WY HB0013: Ivermectin-no prescription required.